# Impact of GBA1 variants on long-term clinical progression and mortality in incident Parkinson’s disease

**Authors:** Thomas B Stoker, Marta Camacho, Sophie Winder-Rhodes, Ganqiang Liu, Clemens R Scherzer, Thomas Foltynie, Jonathan Evans, David P Breen, Roger A Barker, Caroline H Williams-Gray

PMC · DOI: 10.1136/jnnp-2020-322857 · Journal of Neurology, Neurosurgery, and Psychiatry · 2020-04-17

## TL;DR

This study shows that GBA1 gene variants, even those not causing Gaucher disease, are linked to faster disease progression and higher mortality in Parkinson’s disease patients.

## Contribution

The study demonstrates that both pathogenic and non-pathogenic GBA1 variants accelerate Parkinson’s disease progression and mortality.

## Key findings

- GBA1 variants were found in 14.4% of Parkinson’s disease patients.
- Pathogenic and non-pathogenic GBA1 variants are associated with faster development of dementia and more severe motor symptoms.
- Pathogenic GBA1 variants are linked to earlier mortality, independent of dementia development.

## Abstract

Variants in the GBA1 gene have been identified as a common risk factor for Parkinson’s disease (PD). In addition to pathogenic mutations (those associated with Gaucher disease), a number of ‘non-pathogenic’ variants also occur at increased frequency in PD. Previous studies have reported that pathogenic variants adversely affect the clinical course of PD. The role of ‘non-pathogenic’ GBA1 variants on PD course is less clear. In this study, we report the effect of GBA1 variants in incident PD patients with long-term follow-up.

The study population consisted of patients in the Cambridgeshire Incidence of Parkinson’s disease from General Practice to Neurologist and Parkinsonism: Incidence, Cognition and Non-motor heterogeneity in Cambridgeshire cohorts. Patients were grouped into non-carriers, carriers of ‘non-pathogenic’ GBA1 variants and carriers of pathogenic GBA1 mutations. Survival analyses for time to development of dementia, postural instability and death were carried out. Cox regression analysis controlling for potential confounders were used to determine the impact of GBA1 variants on these outcome measures.

GBA1 variants were identified in 14.4% of patients. Pathogenic and ‘non-pathogenic’ GBA1 variants were associated with the accelerated development of dementia and a more aggressive motor course. Pathogenic GBA1 variants were associated with earlier mortality in comparison with non-carriers, independent of the development of dementia.

GBA1 variants, including those not associated with Gaucher disease, are common in PD and result in a more aggressive disease course.

## Linked entities

- **Genes:** GBA1 (glucosylceramidase beta 1) [NCBI Gene 2629]
- **Diseases:** Parkinson’s disease (MONDO:0005180), Gaucher disease (MONDO:0018150), dementia (MONDO:0001627)

## Full-text entities

- **Genes:** GBA1 (glucosylceramidase beta 1) [NCBI Gene 2629] {aka GBA, GCB, GLUC}, F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}
- **Diseases:** GD (MESH:D005776), Depression (MESH:D003866), PICNICS (MESH:D010302), Cognitive decline (MESH:D003072), gait disability (MESH:D020234), death (MESH:D003643), MDS (MESH:D009190), Movement Disorder (MESH:D009069), rapid eye movement sleep-behaviour disorder (MESH:D020187), Dementia (MESH:D003704), PD (MESH:D010300), GBA1 abnormalities (MESH:D000014), lysosomal storage disorder (MESH:D016464), kinetic tremor (MESH:D014202), Mental Disorders IV (MESH:D001523), PIGD (MESH:D054972),  (MESH:D018450)
- **Chemicals:** MEGA (-), levodopa (MESH:D007980)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** L444P, c.762 18T>A, T369M, c.589 86A>G, E326K, R257Q, R463C, R48W, E388K, N426K, G10S, L119L, N370S

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC7361014/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC7361014/full.md

## References

33 references — full list in the complete paper: https://tomesphere.com/paper/PMC7361014/full.md

---
Source: https://tomesphere.com/paper/PMC7361014